Bright Minds Biosciences (DRUG) Q4 2025 earnings summary

Executive summary

• Clinical-stage biotech focused on serotonergic therapeutics for CNS disorders, with lead candidate BMB-101 in Phase 2 trials for epilepsy and Prader-Willi Syndrome, and additional preclinical programs in depression and pain.

• Net loss of $12.2M for FY2025, up from $2.8M in FY2024, driven by increased R&D and operational expenses as pipeline advanced.

• Raised $82.1M in equity during FY2025, including a $35M private placement and $33.5M via at-the-market (ATM) program, resulting in $82.9M cash at year-end.

• Sufficient cash to fund operations for at least 12 months; no revenues generated to date.

Financial highlights

• Cash and cash equivalents: $82.9M as of September 30, 2025 (up from $5.7M in 2024).

• Net loss: $12.2M for FY2025 (vs. $2.8M in FY2024).

• R&D expenses: $11.1M in FY2025 (vs. $1.2M in FY2024), reflecting increased clinical activity.

• Weighted average shares outstanding: 6.88M (FY2025); 7.64M shares issued and outstanding at year-end.

• No revenue recognized; negative operating cash flow continues.

Outlook and guidance

• Plans to continue Phase 2/3 clinical development of BMB-101 in epilepsy and initiate Phase 2 in Prader-Willi Syndrome.

• Preclinical candidate BMB-105 expected to enter Phase 1 studies.

• May utilize ATM program for additional capital raises, subject to market conditions.

• Sufficient cash for at least 12 months of operations; ongoing need for additional capital for long-term development.